Tirzepatide
Dual-Pathway Metabolic Support
- Designed to engage both GLP-1 and GIP pathways for dual hormonal signaling
- May support a balanced blood sugar response throughout the day
- May reinforce natural satiety signaling after meals
- Convenient once-weekly subcutaneous injection
- May offer broader metabolic coverage than single-pathway peptides
- May support metabolic rhythm alongside nutrition and movement
Tirzepatide is a dual agonist that engages both GLP-1 and GIP receptors — two complementary hormone pathways your body uses to regulate blood sugar, satiety, and how energy is stored and used. The combination is designed to support the metabolic signaling network more comprehensively than activating a single pathway.
Requires physician review and prescription approval
Common questions
What is tirzepatide?
A dual agonist peptide that activates both GLP-1 and GIP receptors — two complementary hormone pathways your body uses to regulate blood sugar, satiety, and how energy is stored and used. Tirzepatide mimics natural hormones released after meals for broader metabolic signaling than single-pathway options alone.
How is it administered?
A once-weekly subcutaneous injection, self-administered at home with a small needle. A prescribing provider would walk you through dosing and technique as part of your protocol.
Who might consider tirzepatide?
Adults whose goals span blood sugar balance, satiety, and body composition — and who want a dual-pathway approach alongside nutrition and movement. A prescribing provider would evaluate whether it's appropriate based on your individual medical history and goals.
Who should not take tirzepatide?
Tirzepatide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pancreatitis, or active malignancy — and is not recommended during pregnancy or breastfeeding. Additional contraindications may apply based on your medications or medical history.
What are the potential side effects?
The most common are gastrointestinal — nausea, reflux, constipation, or reduced appetite — and these typically ease after the first few weeks as your body adjusts. Rare but serious risks include pancreatitis, gallbladder issues, and allergic reactions. A prescribing provider would review the full risk profile with you before starting.
Do I still need to focus on nutrition and movement?
Yes. Tirzepatide supports your body's own metabolic signaling across two hormone pathways, but sustained results depend on the lifestyle habits that sit alongside it. Think of it as a complement to nutrition and movement, not a replacement.
Important information about compounded GLP-1 therapies
If and when these therapies are available through Nuvara, compounded semaglutide and tirzepatide would be prepared by a licensed US compounding pharmacy based on an individual prescription, where permitted under FDA compounding rules. Compounded versions are not the same as FDA-approved branded drug products and are not interchangeable with them. FDA-approved branded versions of these compounds exist and may be appropriate for some patients; your prescribing clinician will help you understand the differences and determine what fits your situation.
GLP-1 therapies are not appropriate for everyone and carry known risks, including but not limited to: thyroid C-cell tumors (based on findings in animal studies), pancreatitis, gallbladder disease, kidney injury, and serious hypoglycemia when combined with certain other medications. They should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Any decisions about prescribing, dosing, informed consent, and ongoing monitoring would be made by the prescribing provider — not by Nuvara.
Interested in metabolic balance?
Share your goals, and we'll be in touch when Nuvara early access opens in your area.
Join Waitlist to Claim $100 Credit →